Sebastian Oltean

This study identifies SRPK1 as a key regulator of docetaxel resistance in prostate cancer by modulating splicing and apoptosis pathways.

This study shows that insulin/IGF1 signaling in podocytes regulates gene transcription by affecting spliceosome function and protein modifications.

This paper identifies AZT as a potential therapeutic for NF1 tumors through cross-species genetic analysis and validates its efficacy in human and mouse models.

This study investigates three chemicals (LLSOs) that modulate epithelial-mesenchymal transition in prostate cancer cells, showing inhibition of migration and tumor growth in vivo.

The paper investigates the role of BCL-X splice isoforms in diabetic kidney disease, finding that increased BCL-XS promotes apoptosis and correlates with renal function decline, suggesting it as a biomarker and therapeutic target.

This study identifies three compounds that increase VEGF-A165b expression in podocytes by modulating splicing through CLK1 kinase, suggesting CLK1 activation as a potential therapeutic strategy for diabetic nephropathy.

This study investigates SRPK1 expression across multiple cancer types using multi-omics data, finding its association with poor survival and chemoresistance.

This paper shows that inhibiting SRPK1 in monocytes promotes angiogenesis by altering VEGF splicing from anti-angiogenic VEGF-A165b to pro-angiogenic VEGF-A165a in both human and mouse models of peripheral arterial disease.

The paper shows androgen-regulated ESRP2 transcription controls alternative splicing in prostate cancer, with implications for metastasis.